Grace Therapeutics Inc. (GRCE) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear

Grace Therapeutics Inc.

NASDAQ: GRCE · Real-Time Price · USD
3.10
0.02 (0.65%)
At close: Sep 26, 2025, 3:59 PM
3.09
-0.16%
After-hours: Sep 26, 2025, 07:22 PM EDT

Grace Therapeutics Income Statement

Financials in USD. Fiscal year is April - March.
Fiscal Year FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Mar 31, 2025 Mar 31, 2024 Mar 31, 2023 Mar 31, 2022 Mar 31, 2021
Revenue
n/a n/a n/a n/a 196K
Cost of Revenue
7K 11K 124K n/a 76K
Gross Profit
-7K -11K -124K n/a 120K
Operating Income
-16.68M -12.85M -52.16M -15.59M -16.42M
Interest Income
711K 911K 246K 77K 107K
Pretax Income
-12.77M -14.69M -51.97M -10.47M -19.68M
Net Income
-12.77M -12.85M -42.43M -9.82M -19.68M
Selling & General & Admin
7.17M 6.64M 8.21M 9.78M 6.66M
Research & Development
9.51M 4.68M 9.97M 5.56M 4.17M
Other Expenses
n/a 1.52M 33.97M 249K 5.71M
Operating Expenses
16.68M 12.85M 52.16M 15.59M 16.54M
Interest Expense
n/a n/a n/a n/a 264K
Selling & Marketing Expenses
n/a 194K 136K 116K 1.14M
Cost & Expenses
16.68M 12.85M 52.16M 15.59M 16.61M
Income Tax Expense
-3.2M -1.83M -9.54M -648K n/a
Shares Outstanding (Basic)
12.09M 7.44M 7.43M 6.14M 2.47M
Shares Outstanding (Diluted)
12.09M 7.44M 7.43M 6.14M 2.47M
EPS (Basic)
-0.79 -1.73 -5.71 -1.6 -7.98
EPS (Diluted)
-0.79 -1.73 -5.71 -1.6 -7.98
EBITDA
-12.76M -11.33M -18.12M -15.34M -9.79M
EBIT
-12.77M -11.37M -18.25M -15.34M -10.72M
Depreciation & Amortization
7K 11K 124K n/a 924K